Multicentre, Single-arm, Open Label Clinical Trial Intended to Provide Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen and to Document Safety of Cabazitaxel in These Patients.

Trial Profile

Multicentre, Single-arm, Open Label Clinical Trial Intended to Provide Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen and to Document Safety of Cabazitaxel in These Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Cabazitaxel (Primary) ; Prednisolone; Prednisone
  • Indications Prostate cancer
  • Focus Expanded access; Registrational; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 06 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
    • 06 Jan 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
    • 15 May 2014 Planned End Date changed from 1 Apr 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top